Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis.

Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Experimental Parasitology (Impact Factor: 2.15). 05/2011; 129(1):55-64. DOI: 10.1016/j.exppara.2011.05.014
Source: PubMed

ABSTRACT The acidic ribosomal proteins of the protozoan parasites have been described as prominent antigens during human disease. We present here data showing the molecular cloning and protective efficacy of P1 gene of Leishmania donovani as DNA vaccine. The PCR amplified complete ORF cloned in either pQE or pVAX vector was used either as peptide or DNA vaccine against experimentally induced visceral leishmaniasis in hamsters. The recombinant protein rLdP1 was given along with Freund's adjuvant and the plasmid DNA vaccine, pVAX-P1 was used alone either as single dose or double dose (prime and boost) in different groups of hamsters which were subsequently challenged with a virulent dose of 1×10(7) L. donovani (MHOM/IN/DD8/1968 strain) promastigotes by intra-cardiac route. While the recombinant protein rLdP1 or DNA vaccine pVAX-P1 in single dose format were not found to be protective, DNA vaccine in a prime-boost mode was able to induce protection with reduced mortality, a significant (75.68%) decrease in splenic parasite burden and increased expression of Th1 type cytokines in immunized hamsters. Histopathology of livers and spleens from these animals showed formation of mature granulomas with compact arrangement of lymphocytes and histiocytes, indicating its protective potential as vaccine candidate.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Disorganized muscle family member (Dim-1) belongs to immunoglobulin superfamily, and is a structural protein localized to the region of the muscle cell membrane around and between the dense bodies. Strong immunogenicity to host's immune system was induced by Dim-1 from Ascaris suum, which indicated that Dim-1 could be a potential candidate for vaccine. The homologues of Dim-1 were also detected in nematodes Brugia malayi and Trichostrongylus colubriformis. However, information on the complete coding sequence and protection potential of this molecule in Haemonchus contortus is lacking. In this study, full length of Dim-1 cDNA was cloned using a rapid amplification of cDNA ends (RACE) strategy and the DNA vaccine encoding Dim-1 open reading frame (ORF) was tested for protection against experimental H. contortus infections in goats. Fifteen goats were allocated into three trial groups. The animals of Dim-1 group were vaccinated with the DNA vaccine encoding Dim-1 on day 0 and 14, and challenged with 5000 infective H. contortus third larval stage (L3) on day 28. An unvaccinated positive control group was challenged with L3 at the same time. An unvaccinated negative control group was not challenged with L3. The results indicated Dim-1 DNA vaccines were transcribed at local injection sites and expressed in vivo post immunizations respectively. Following L3 challenge, the mean eggs per gram feces (EPG) and worm burdens of Dim-1 group were reduced by 45.7% and 51.1%, respectively. Significantly high levels of serum IgG, serum IgA, mucosal IgA, CD4(+) T lymphocytes and B lymphocytes of Dim-1 group were produced. While compared with the negative control group, increased numbers of blood eosinophils and lymphocytes and declined haemoglobin level were observed in the Dim-1 group after L3 challenge. The preliminary study suggest that recombinant H. contortus Dim-1 DNA vaccine induced partial immune response and has protective potential against goat haemonchosis.
    Research in Veterinary Science 03/2013; · 1.77 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although a great deal of knowledge has been gained from studies on the immunobiology of leishmaniasis, there is still no universally acceptable, safe, and effective vaccine against the disease. This strongly suggests that we still do not completely understand the factors that control and/or regulate the development and sustenance of anti-Leishmania immunity, particularly those associated with secondary (memory) immunity. Such an understanding is critically important for designing safe, effective, and universally acceptable vaccine against the disease. Here we review the literature on the correlate of protective anti-Leishmania immunity and vaccination strategies against leishmaniasis with a bias emphasis on experimental cutaneous leishmaniasis.
    Frontiers in Immunology 01/2012; 3:128.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We previously reported that the chimeric DNA vaccine pcDNA-3-1E-linker-mChIL-15, fused through linking Eimeria acervulina 3-1E encoding gene and mature chicken IL-15 (mChIL-15) gene with four flexible amino acid SPGS, could significantly offer protection against homologous challenge. In the present study, the induction of cellular immune response induced by the chimeric DNA vaccine pcDNA-3-1E-linker-mChIL-15 was investigated. Spleen lymphocyte subpopulations were characterized by flow cytometric analysis. The spleen lymphocyte proliferation assays were measured by 3-[4,5-dimethylthiazol-2-y1]-2,5-diphenyltetrazolium bromide (MTT) method. The mRNA profiles of ChIL-2 and ChIFN-γ in spleen were characterized by means of real-time PCR. Chickens immunized with pcDNA-3-1E-linker-mChIL-15 exhibited significant upregulated level of ChIL-2 and ChIFN-γ transcripts in spleen following two immunizations compared with chickens in other groups (P < 0.01). In comparison with pcDNA3.1-immunized and control groups, lymphocyte proliferation, percentage of CD8α(+) cell, and levels of ChIL-2 and ChIFN-γ transcripts in the group immunized with pcDNA-3-1E-linker-mChIL-15 were significantly increased on day 6 following challenge (P < 0.05, P < 0.01, and P < 0.01, resp.). Our data suggested that the fusion antigen 3-1E-linker-mChIL-15 could be a potential candidate for E. acervulina vaccine development.
    Journal of Parasitology Research 01/2012; 2012:654279.